Tags » Fabrazyme

Genzyme Announces $80M to Build a Fabrazyme Facility

Framingham, Mass – Genzyme, a Sanofi company, announced today that it is investing $80 million to build a new downstream processing facility for Fabrazyme(R) (agalsidase beta). 169 more words

Widow's Lawsuit Claims Drug Shortage Led To Husband's Death

If you or your loved one were in desperate need of a lifesaving drug, and it was unavailable due to a drug shortage, what would you do?  154 more words

Drug Safety News

Delays, delays...

Perhaps one of many reasons Genzyme seems more willing to talk with sanofi-aventis about possibly being acquired in a peaceful fashion instead of in a hostile takeover (or having no deal at all)? 70 more words

Corporate

Early access to second treatment for Fabry disease

The FDA has approved early access to Replagal ®, a second treatment for Fabry disease, as Shire prepares to apply for FDA approval to provide commercial treatment in the U.S. 34 more words

Agalsidase beta:

U.S. BRAND NAMES — Fabrazyme®
PHARMACOLOGIC CATEGORY Enzyme
DOSING: ADULTS — Fabry disease: I.V.: 1 mg/kg every 2 weeks
DOSING: ELDERLY — Refer to adult dosing. 544 more words

Agalsidase Beta

Agalsidase beta

U.S. BRAND NAMES — Fabrazyme®
PHARMACOLOGIC CATEGORY Enzyme
DOSING: ADULTS — Fabry disease: I.V.: 1 mg/kg every 2 weeks
DOSING: ELDERLY — Refer to adult dosing. 539 more words

Agalsidase Beta